Posted September 29, 2012
Study: GSK melanoma combination slows cancer progress
Research Triangle Park, N.C. —Patients taking Glaxo's dabrafenib and trametinib together delayed tumors from progressing for 9.4 months, compared with 5.8 months for patients taking dabrafenib alone, according to the study of 162 patients. The trial was part of the second of three phases of human testing usually required by regulators....Copyright 2013 Bloomberg. All rights reserved.
Please log in to view WRALTechWire Insider content
Please Log In to add a comment.